These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 18596282

  • 1. Drug-review deadlines and safety problems.
    Nardinelli C, Lanthier M, Temple R.
    N Engl J Med; 2008 Jul 03; 359(1):95-6; author reply 96-8. PubMed ID: 18596282
    [No Abstract] [Full Text] [Related]

  • 2. Drug-review deadlines and safety problems.
    Carpenter D, Zucker EJ, Avorn J.
    N Engl J Med; 2008 Mar 27; 358(13):1354-61. PubMed ID: 18367738
    [Abstract] [Full Text] [Related]

  • 3. Bolstering the FDA's drug-safety authority.
    Schultz WB.
    N Engl J Med; 2007 Nov 29; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract] [Full Text] [Related]

  • 4. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan 29; 71(1):34-9. PubMed ID: 16491527
    [No Abstract] [Full Text] [Related]

  • 5. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M.
    Seton Hall Law Rev; 2007 Jan 29; 37(4):941-68. PubMed ID: 18363218
    [No Abstract] [Full Text] [Related]

  • 6. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM, Studdert DM, Brennan TA.
    N Engl J Med; 2009 Apr 09; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract] [Full Text] [Related]

  • 7. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED, Ciociola AA, Kulkarni PM, FDA-Related Matters Committee of the American College of Gastroenterology.
    Am J Gastroenterol; 2012 Apr 09; 107(4):501-4. PubMed ID: 22475958
    [No Abstract] [Full Text] [Related]

  • 8. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M.
    N Engl J Med; 2007 Apr 26; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract] [Full Text] [Related]

  • 9. Legal overprotection.
    Friedman JH.
    Med Health R I; 2004 Oct 26; 87(10):294. PubMed ID: 15559378
    [No Abstract] [Full Text] [Related]

  • 10. Post-marketing strategies for medicines.
    Breckenridge A.
    Clin Pharmacol Ther; 2008 Jan 26; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract] [Full Text] [Related]

  • 11. The marketplace can't give us the drug safety data we need.
    Avorn J.
    MedGenMed; 2007 Feb 09; 9(1):29. PubMed ID: 17435636
    [No Abstract] [Full Text] [Related]

  • 12. What ails the FDA?
    Okie S.
    N Engl J Med; 2005 Mar 17; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract] [Full Text] [Related]

  • 13. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S, Roberts R.
    J Allergy Clin Immunol; 2006 Jan 17; 117(1):34-9. PubMed ID: 16387581
    [Abstract] [Full Text] [Related]

  • 14. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH, Annas GJ.
    N Engl J Med; 2011 Aug 25; 365(8):681-3. PubMed ID: 21830958
    [No Abstract] [Full Text] [Related]

  • 15. Canadian and US drug approval times and safety considerations.
    Rawson NS, Kaitin KI.
    Ann Pharmacother; 2003 Oct 25; 37(10):1403-8. PubMed ID: 14519031
    [Abstract] [Full Text] [Related]

  • 16. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S, Strom BL.
    N Engl J Med; 2007 Apr 26; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract] [Full Text] [Related]

  • 17. "Safer, but not safe enough".
    Crombie HD.
    Conn Med; 2006 Apr 26; 70(10):645. PubMed ID: 17190395
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Paying for drug approvals--who's using whom?
    Avorn J.
    N Engl J Med; 2007 Apr 26; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract] [Full Text] [Related]

  • 20. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE, Farrell AT, Pazdur R, Woodcock J.
    Oncologist; 2010 Apr 26; 15 Suppl 1():13-8. PubMed ID: 20237212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.